Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Bevacizumab in Hemodialysis Patients
NCT02695641Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of bevacizumab in vascular access failure (VAF) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Change in Serum concentration of bevacizumab at 4 weeks and Change in plasma free VEGF-A levels at 4 weeks. Planned start Aug 2019; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
vascular access failure (VAF)
Beyond the preview
Go deeper on NCT02695641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695641.